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Abstract: Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in
achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic
leukaemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). However, there are limitations,
including inability to manufacture CAR-T cells from the patient’s own T cells, disease progression
and death prior to return of engineered cells. T cell dysfunction is known to occur in cancer patients,
and several groups have recently described differences in CAR-T cells generated from chronic
lymphocytic leukaemia (CLL) patients compared with those from a healthy donor. This is thought
to contribute to the low response rate in this disease group. Healthy donor, gene-edited CAR-T
cells which do not require human leucocyte antigen (HLA) matching have the potential to provide
an ‘off the shelf’ product, overcoming the manufacturing difficulties of producing CAR-T cells for
each individual patient. They may also provide a more functional, potent product for malignancies
such as CLL, where T cell dysfunction is common and frequently cannot be fully reversed during
the manufacturing process. Here we review the potential benefits and obstacles for healthy donor,
allogeneic CAR-T cells.
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1. Introduction
Immune surveillance is the process by which the immune system is believed to detect and destroy
cancerous cells before clinical malignancy develops. Therefore, for a patient to develop a tumour their
malignant cells must have evaded immune elimination. Immunotherapy-based treatment strategies
have been around for many years and are designed to enhance and manipulate immune responses
to cause tumour regression. Chimeric antigen receptor-T (CAR-T) cells are one such emerging
immunotherapy whereby T cells are genetically modified to recognise a particular antigen that the
tumour cells are known to display. These engineered T cells express an artificial receptor consisting
of an antigen recognition domain, typically a single chain variable fragment (scFv), a co-stimulatory
domain (usually 4–1BB or CD28) and an intracellular CD3ζ signaling domain. The majority of CAR-T
cell studies have used autologous T cells collected from patients which are transduced, usually with a
viral vector (lentivirus or retrovirus), introducing the CAR construct. Transduced T cells are expanded
ex vivo and then infused back into patients following lymphodepleting chemotherapy. This technology
has overcome several strategies that malignant cells adopt to hide from the immune system and avoid
immune destruction. Tumour cells can downregulate human leucocyte antigen (HLA) expression, but
unlike a normal T cell receptor the CAR does not require the HLA complex for antigen recognition and
binding. In addition, tumour cells have reduced expression of co-stimulatory molecules and increased
expression of inhibitory molecules impairing T-cell response [1]. The co-stimulatory domain within
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the CAR construct bypasses the need for tumour cells to express co-stimulatory molecules and to some
extent ameliorates the effect of immune checkpoint expression.
The clinical efficacy of this technology has been proven, with stunning complete remission
rates (CR) in B-acute lymphoblastic leukaemia (>80% of patients) [2,3] and promising early data in
diffuse large B-cell lymphoma (DLBCL) (>40% CR) [4,5]. However, there are major limitations to
accessing this technology. Currently, it is a bespoke product made for individual patients, therefore
the time to manufacture can prevent access, as can the cost. Furthermore, the T cells used as starting
material from patients are likely to have developed cancer associated T cell dysfunction which may
not be reversible [6]. Healthy donor allogeneic CAR-T cells can be derived from patients’ previous
haematopoietic stem cell transplant (HSCT) donor, who they are HLA matched to or from gene edited
cells which have been modified to allow them to be given to non-HLA matched patients. Here we
review the limitations of patient derived (PD) CAR-T cells and discuss the potential benefit and
challenges of healthy donor (HD) CAR-T cells. Figure 1 summarises the obstacles of using PD and HD
CAR-T cells.
Figure 1. Challenges of using healthy donor and patient derived chimeric antigen receptor-T (CAR-T cells).
2. Limitations of Patient Derived, Autologous Chimeric Antigen Receptor-T (CAR-T Cells)
2.1. Cost
The first FDA approved PD CAR-T cell product, Tisagenlecleucel, from Novartis, licenced to
treat paediatric and young adult B-ALL, is priced at $475,000 US dollars per patient [7]. KITE/Gilead
anti-CD19 CAR-T cell product, Axicabtagene ciloleucel, for DLBCL, is being marketed at $373,000
USD per patient [8] and Novartis have matched this price when using their product in the setting of
lymphoma. This cost is purely for the T cell manufacture and excludes other aspects of patient care,
which are likely to be high as patients frequently require admission to intensive care.
2.2. Harvest and Manufacturing Failures
It is not always possible to harvest and manufacture adequate lymphocyte numbers from
patients who are typically lymphopenic from their disease or previous chemotherapy. It is likely
that severely lymphopenic patients are those most heavily pre-treated and therefore may represent
a particularly poor risk group. The multicentre ZUMA-1 study, using Axicabtagene ciloleucel, in
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DLBCL, only included patients with a lymphocyte count > 100/µL [5]. Published response rates often
exclude patients with an insufficient lymphocyte harvest. Indeed, the multinational ELIANA study, in
which Tisagenlecleucel was used to treat paediatric and young adult B-ALL, lists having an adequate
apheresis product received by the manufacturer as one of the criteria for enrolment [2]. Despite this
stipulation manufacturing failures still occur. In the ELIANA study, 7.6% of patients did not receive
the cells due to ‘product related issues’ [2], this was even higher using the same CAR construct in
adults with DLBLC or follicular lymphoma (FL) with 13.2% manufacturing failure cases (all patients
with manufacturing failure had an absolute lymphocyte count < 300/µL) [4].
2.3. Product Variability and Quality Control
As cells are manufactured for each individual patient from their apheresis collection it is not
possible to produce a completely standardised end product. Attributes which are thought to be key
such as cell number, viability, CAR expression and memory phenotype can be monitored but will not
be entirely consistent from product to product [9]. Manufacturing processes are being optimised in
an attempt to ensure the quality of the product, for example by using high titre purified lentivirus [9]
but problems of viability and varying phenotype remain challenging.
2.4. Disease Progression During Manufacture
Disease progression during manufacture is a significant barrier to accessing this technology. In the
JULIET study, where Tisagenlecleucel was used to treat relapsed, refractory DLBCL and FL, 13% of
patients never received the CAR-T cell product due to disease progression [4]. Using the same product
in paediatric and young adult B-ALL, 7.6% of enrolled/leukapheresed patients died before receiving
the CAR-T cells [2]. Manufacture typically takes 14–21 days, but may decrease as improvements are
made in production.
2.5. Contamination with Tumour Cells
Patients with refractory disease often have circulating leukaemia cells in the blood which are
harvested during leukapheresis. These tumour cells are killed by transduced T cells during the
manufacturing process. However, cases have been reported where the leukaemia cell is transduced
by the CAR construct, which when expressed is thought to block its own CD19 antigen, preventing
engagement by CAR-T cells. This has lead to relapsed leukaemia cells which express the CAR
construct [10].
2.6. T Cell Dysfunction
Chronic lymphocytic leukaemia (CLL), like B-ALL and DLBCL is a CD19 expressing B cell
malignancy with a similar anatomical distribution of disease (bone marrow and lymphoid organs).
However, results from clinical trials using anti-CD19 CAR-T cells have been disappointing with only
26% of patients having a sustained response [11]. Investigators have been unable to identify tumour
related characteristics which predict response to CAR-T cell therapy [12]. T cell dysfunction is well
described in CLL and is more marked in advanced disease [13]. Fraietta and colleagues carried out
a thorough evaluation of the apheresed T cells and CAR-T cell product from responding (CR) and
non-responding (NR) CLL patients [12]. They found expansion during manufacture was a simple
predictor of response and correlated with proliferation in vivo which is necessary for CAR-T cells to
have sustained anti-tumour activity. When the CAR-T cell product from CR patients was compared to
those from NR patients in an immunodeficient murine xenograft model (NSG mice engrafted with the
CD19 positive NALM-cell line), CR patient derived CAR-T cells expanded more and caused superior
tumour regression. This lead to prolonged survival compared to those treated with NR patient derived
CAR-T cells, suggesting that it is the T cell product as opposed to tumour related factors which were
influencing response [12].
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A comparison of the gene expression profile of NR and CR patient derived CAR-T cells found
those from NR patients expressed more exhaustion markers and genes associated with effector
differentiated T cells [12]. In contrast, those derived from CR patients had a signature consistent
with an early memory stage phenotype [12]. In this model, HD CAR-T cells were used as a control and
performed at least as well as the CAR-T cell product from CR patients. Mice treated with HD CAR-T
cells had the longest survival and showed sustained tumour regression [12] supporting the hypothesis
that HD CAR-T cells may provide a more functional anti-leukaemia product, at least in the context of
CLL and other malignancies characterised by T cell dysfunction. Interestingly, the authors also found
a higher frequency of CD27+CD45RO−CD8+ T cells before manufacture correlated with response [12].
Screening and selecting healthy donors with high frequency of these cells is therefore an appealing
therapeutic strategy that may improve outcome.
A study by Hoffman et al. compared the phenotype and expansion of CAR-T cells from untreated
CLL patients with those from HDs [14]. CAR-T cells from untreated CLL patients might be expected
to show less T cell dysfunction than those from the heavily pre-treated, relapsed/refractory patients
receiving CAR-T cells in clinical trials. The numbers in each group were low (n = 3) but there was
greater expansion in naive CAR-T cells (CD45RA+CCR7+) from HDs as compared to untreated CLL
patients, who had greater expansion in effector CAR-T cells (CD45RA+CCR7−) [14]. Conflicting results
were found by another team but their expansion time following transduction was much shorter at
5–8 days [15]. PD1 expression was significantly higher on naïve and central memory CAR-T cells from
untreated CLL patients as compared to HDs [14]. Fraietta et al. describe a CD8+CAR+CD27+PD1−
population of cells as an important predictor of response in patients. In functional assays, removal of
this population resulted in lack of tumour control [12].
T cell dysfunction is a clear risk factor for B-cell lymphoma [16]. Post-transplant lymphoproliferative
disorder occurs in patients who have received immunosuppressive drugs to impair their T cells (to prevent
graft rejection). In addition, HIV infection also predisposes to DLBCL, Burkitt’s lymphoma and other
malignancies [17]. Furthermore, it has previously been described that DLBCL patient derived T cells
proliferate less in response to polyclonal activation compared to those from a healthy donor [18]. T cell
defects have also been reported in myeloma patients and some solid organ malignancies [19]. Whether this
translates into less functional CAR-T cells in malignancies besides CLL needs to be evaluated.
HD allogeneic CAR-T cells could potentially provide an alternative source of CAR-T cells for
patients in whom harvest failures occur and in those with rapidly progressive disease who cannot wait
for autologous CARs to be manufactured. Additionally, HD CAR-T cells may overcome the problems
of T cell dysfunction seen in malignancy and provide a more potent product. One donor could provide
therapeutic cells for multiple patients, with a standardised treatment being manufactured at reduced
cost. Donors with a T cell phenotype associated with superior CAR-T cell function could be identified
maximizing the quality of the product. Redosing for the same patient can also be done more readily
with HD CAR-T cells. However, there are challenges to using HD CAR-T cells that still need to
be overcome.
3. Barriers to Allogeneic, Healthy Donor CAR-T cells
3.1. Graft Versus Host Disease (GVHD)
Graft Versus Host Disease (GVHD) results from donor derived T-cells recognising HLA mismatch
via the T cell αβ receptor (TCRαβ) and attacking patient’s tissues. It can be fatal even in the
HLA matched donor setting, as minor mismatches may still provoke the response, and is a major
complication of HSCT. It can also occur following transfusion, but due to widespread leucodepletion of
blood products and irradiation for at risk groups (generally those who are heavily immunosuppressed
e.g., after purine analogue chemotherapy), it is now rarely seen. To make HD CAR-T cells safe,
GVHD must be prevented.
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3.2. Rejection of CAR-T Cells
A patient’s T-cells will recognise infused non-HLA matched T-cells as foreign and reject them.
HLA matching has reduced graft rejection in HSCT. Not all patients have a fully matched donor and it
would be desirable to have a readily available cellular product suitable for all patients independent of
HLA type. Intensification of patient lymphodepletion may be sufficient to allow HD CAR-T cells to
expand and clear malignant cells, prior to host immune recovery. To enable this, several strategies are
being deployed to make donor T-cells resistant to lymphodepleting agents.
4. Strategies to Deploy Allogeneic CAR-T Cells
4.1. Manufacture of CAR-T Cells from Previous Allogeneic Haematopoietic Stem Cell Transplant (HSCT) Donor
HSCT is the standard of care for high risk B-ALL patients with an HLA matched donor. It is
not uncommon for adult patients to relapse post HSCT, therefore clinical trials have evaluated the
use of CAR-T cells derived from the same donor. As these donors are HLA matched to the patient,
CAR-T cells generated from them are less likely to cause GVHD and, as they are identical to the
previously transplanted haematopoietic compartment, they should not attack the graft. Early results
show minimal GVHD in contrast to standard Donor Lymphocyte Infusion (DLI) [20] where the rate of
acute GVHD is 40–60% [21]. One study reported no acute GVHD at all, although no lymphodepletion
was given, so Tregs would have persisted, ameliorating GVHD and potentially the CAR-T cell activity.
This strategy resulted in fairly low anti-leukaemia activity (40% remission rate) [20].
The type of co-stimulatory domain used in the CAR-T cell construct appears to impact on the
degree of GVHD, with a reduction when a CD28 co-stimulatory domain is used. It is hypothesised
that donor derived CAR-T cells with a CD28 co-stimulatory domain receive signals both via the CAR
and the TCRαβ resulting in increased exhaustion and cell death as compared to CAR-T cells receiving
stimulation via a 41-BB co-stimulatory domain and the endogenous TCRαβ [22,23].
While HSCT donor derived CAR-T cells provide an alternative source of cells for a selected
patient group, and may overcome T cell dysfunction, they are not ‘off the shelf’. They still need to
be manufactured for each individual patient, whose disease must be controlled during this process.
26% of patients consenting to the NCI/NIH study for CD19 positive B cell malignancies never received
the CAR-T cell infusion due to progressive disease and/or medical complications [20]. What is more,
allogeneic HSCT is rarely used as a treatment strategy in relapsed DLBCL or CLL and certainly would
not be a practical ‘bridge’ to providing an allogeneic CAR-T cell product.
4.2. ‘Off the Shelf’ Virus Specific CAR-T Cells
Unlike HSCT donors, third party viral specific (VS) T cell donors are only partial HLA
matched (1–4 alleles) to patients. These cells have been used to treat viral infections following
transplantation [24]. Despite HLA mistmatches they only show minimal GVHD and in responding
patients persisted between 14 and 90 days [25]. They are therefore an appealing source of cells for
manufacturing allogeneic CAR-T cells [26]. However, response rates using HSCT donor derived
VS CAR-T cells have been disappointing with 1 out of 6 patients treated achieving a CR [27] and
the efficacy of using only partially HLA matched VS CAR-T cells has not yet been demonstrated.
The requirement for partial HLA matching would also not make these a truly universal product.
4.3. Gene-Edited Healthy Donor CAR-T cells
A universal ‘off the shelf’ CAR T cell product could eliminate a lot of the problems of harvest and
manufacture failures associated with their autologous and HSCT derived counterparts. Although they
are not without their challenges, recent technological advances have been promising in overcoming
many of these.
To prevent GVHD the TCRαβ receptor can be knocked out (KO) by different gene editing
techniques. TCRαβ is a heterodimer and both alpha and beta chains need to be present for it to
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be expressed. A single gene codes for the alpha chain (TRAC), whereas there are 2 genes coding
for the beta chain, therefore TRAC loci KO using nucleases is the choice strategy for removing
TCRαβ expression.
Nucleases act as ‘molecular scissors’ for editing the genome. They use the binding of proteins or
guide RNA (gRNA) to a specific target DNA sequence and then cut it using a nuclease domain. When
they cut DNA it forms a double stranded break (DSB) and due to error prone non-homologous end
joining (NHEJ) the gene is disrupted. Table 1 summarises the gene editing techniques used to KO
TCRαβ for HD CAR-T cell production. Gene editing techniques do not reach 100% knockout and even
with depletion of TCRαβ+ cells, small numbers remain which could theoretically cause GVHD.
Most strategies to produce gene edited HD CAR-T cells use two steps whereby the CAR is
introduced with a viral vector and the TRAC loci disrupted using a nuclease e.g., zinc finger nucleases
(ZFNs) or transcription activator like effector nucleases (TALENs). Using this method, similar to PD
CAR-T cells, the genes encoding the CAR construct integrate in a semi random fashion with variable
expression levels.
Eyquem et al. developed a technique whereby the CAR construct is incorporated into the
TRAC loci, which introduces the CAR and prevents endogenous TCRαβ expression in one step [28].
Additionally, this allows expression of the CAR to be controlled by the TRAC locus resulting in more
uniform expression and prevention of tonic signalling [28]. The authors used a guide RNA targeting
the TRAC loci and Cas9 mRNA, to cut it. To introduce the CAR into the disrupted TRAC site they used
an adeno-associated virus with homology arms to the cut loci carrying CAR cDNA [28]. In a murine
xenograft model, using the B-ALL cell line NALM-6, the authors found that CAR-T cells produced
by this method outperformed CAR-T cells produced by traditional viral transduction. Mice survived
longer and had better tumour control. CAR-T cells also showed less terminal differentiation and lower
expression of the exhaustion markers PD1, LAG3 and TIM3 [28]. Similarly, another group, this time
using a homing endonuclease to disrupt the TRAC loci, introduced the CAR into the cut site with an
adeno-associated virus [29].
A different approach linked CAR expression with TRAC disruption by clustered regularly
interspaced short palindromic repeats (CRISPR)/Cas9 without directly incorporating the CAR into
the TRAC loci. sgRNA sequence for CRISPR was included in the lentiviral vector carrying the CAR.
Cas9 mRNA was then electroporated into transduced cells. TRAC disruption therefore only occurred
in cells successfully transduced with the CAR (and the sgRNA). After magnetic bead depletion to
remove residual unedited cells expressing TCRαβ, the percentage of CAR+ cells was much higher
than current methods, at >99% [30]. These cells showed superior anti-tumour efficacy in a murine
xenograft model than unedited CAR+ cells and less PD1 expression [30]. Using this technique the
authors produced enough CAR+ cells to dose 20 adult patients from a single leukapheresis of a healthy
donor [30]. Advances in gene editing techniques may not only improve access to CAR-T cells but
produce CAR-T cells with superior anti-tumour efficacy.
4.4. Non Gene Edited Mismatch CAR-T Cells
An alternative strategy to prevent GVHD, currently at the developmental stage, is the modification
of CAR-T cells to express an inhibitor of TCRαβ signalling. Gilham et al. report the use of a truncated
form of CD3ζ as a TCR inhibitory molecule, which in an NSG mouse model did not cause GVHD and
retained CAR activity [31]. A clinical trial with this product is planned in colorectal cancer, with the
CAR construct targeting natural killer group 2D (NKG2D) ligands [31]. Solid tumours to date have
not had the dramatic response rates to PD CAR-T cells which have been seen in haematological
malignancies. There are several reasons for this, including heterogenous antigen expression and the
immunosuppressive tumour microenvironment [32]. Solid tumours are known to be associated with T
cell dysfunction [33] and this trial will help explore if HD CAR-T cells can produce better responses.
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4.5. To Prevent CAR-T Cell Rejection
Intensification of lymphodepletion may be sufficient to allow HD CAR-T cells to expand and
clear malignant cells prior to host immune recovery. Several strategies are being deployed to make
donor T-cells resistant to lymphodepleting agents such as Alemtuzumab (monoclonal anti-CD52) [34]
and purine analogues [35]. UCART19 has had CD52 KO with TALENs thus producing resistance to
Alemtuzumab [34]. This has shown promise with expansion and anti-leukaemia activity of these cells
seen in patients with B-ALL [36]. Two clinical trials are currently evaluating UCART19 in adult B-ALL
(CALM, NCT02746952) and Paediatric B-ALL (PALL, NCT02808442).
Gene editing has additionally been used to prevent expression of HLA class I molecules on CAR-T
cells. Torikai et al. used ZFNs to knock out the HLA-A locus [37] but a more decisive approach
was adopted by Ren et al. to target Beta-2 microglobulin (B2M), which is required for HLA class I
expression [38]. This approach prevents host TCRαβ cells recognising donor CAR-T cells as foreign
via HLA class I. However, activated T cells also express HLA Class II which might stimulate rejection.
NK cells also target cells with reduced HLA expression and represent a further challenge to preventing
CAR-T cell rejection [38,39]. Using the CRISPR/Cas9 system researchers have simultaneously KO
TCRαβ, B2M and the immune-checkpoint PD1 which showed enhanced anti-tumour activity in a
NALM6 NSG murine model without inducing GVHD [38]. In China, a clinical trial is recruiting
where HD CAR-T cells have both the TRAC and B2M gene disrupted by CRISPR/Cas9 (NCT03166878)
although outcome data is not yet available. Data on long term persistence and function of CAR-T cells
which have had either TRAC or HLA expression disrupted is not yet available and may be key to
their success.
4.6. Challenges of Gene Editing
Gene editing is revolutionising the possibilities for cellular technologies, but such highly
manipulated products come with unknown risks. Off target cleavage of genes can occur, where
multiple sites are cut, new translocations can occur. In UCART19 recombination between CD52
and TRAC loci is seen, but does not appear to cause a proliferative advantage (Poirot, et al. 2015).
Researchers must remain vigilant to introducing oncogenic potential into edited cells. This issue was
highlighted by Fraietta et al. who reported the incidental disruption of the TET2 gene due to lentivirus
coding for the CAR construct integrating at this site. This resulted in a proliferation and survival
advantage of CAR-T cells with this disruption as compared to those without [40]. Inserting the CAR
construct into the TRAC loci may actually reduce the risk of insertional mutagenesis [29] however,
with new gene editing technologies going into patients, long term safety data is lacking.
Table 1. Summary table of different gene editing techniques used to disrupt T cell αβ receptor
(TCRαβ) expression.
Binding Region Nuclease Cutting Efficiency Reference
Zinc finger nucleases (ZFNs) Protein FOKI 20–40% [41]
Transcription activator-like
effector nuclease (TALEN) Protein FOKI
53.7% (double knockout)
78% TCR KO
78.8 & 81.2%
[34]
[42]
CRISPR/Cas9 gRNA Cas9
60% [43]
>80% [38]
~70% [28]
77% (CAR+ cells) [30]
megaTAL Nucleases Protein Meganuclease 75% [43]
Engineered I-CreI Homing
endonuclease Protein >60% [29]
4.7. Inducible Pluripotent Stem (iPS) Derived CAR-T Cells
To remove the requirement for repeated donations by healthy volunteers and create a bank of
different HLA type CAR-T cell lines, researchers have generated induced pluripotent stem (iPS) CAR-T
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cells [44]. Transducing HD T cells with reprogramming factors can restore pluripotency. The CAR
construct is then introduced by a lentiviral vector. iPS CAR-T cells are capable of self renewal and
additional gene editing steps such as TRAC KO are being proposed, which could provide a continuous
supply of universal CAR-T cells [44]. The safety and efficacy of this approach in humans is not known.
Once re-differentiated T cells had a phenotype most resembling gamma delta (γδ) cells, they had
lower levels of CAR expression and in an immunodeficient xenograft mouse model, resulted in shorter
survival than mice treated with CAR-T cells from normal αβ T cells [44]. This is an intriguing future
source of cells, but numerous obstacles need to be overcome.
5. Discussion
Autologous PD CAR-T cells have shown huge potential in treating patients with CD19 positive
malignancies. However, relapsed refractory cancer patients in whom this therapy has proven so
hopeful, rarely have stable disease. They must wait for an apheresis slot to collect their own
lymphocytes and the manufacturing time for the CAR-T cell product to be made. Patients with
resistant disease are likely to have received multiple lines of intensive chemotherapy, impairing their
own lymphocyte count and function. Furthermore, T cell dysfunction can occur in cancer patients even
in the absence of therapy as exemplified in CLL. CAR-T cells from previous HSCT donors may provide
an alternative supply of cells for a small subset of patients but still need to be produced as a bespoke
product. Healthy donor, gene edited, allogeneic CAR-T cells could provide a readily available, ‘off the
shelf’ product for patients. It is hoped this will decrease the cost per patient, however, gene editing will
add to the complexity of the manufacturing process. HDs may provide a more functional T cell product
and could be screened for a T cell phenotype linked with more potent anti-leukaemia activity such as
CD8+CD27+CD45RO– associated with improved response in the setting of CLL [12]. Donors could
then provide CAR-T cells for multiple patients and a standardised high quality product manufactured.
Gene editing to knockout the TCRαβ receptor is an attractive approach to prevent GVHD that is
being deployed by several groups using ZFNs [41], TALENs [34,36,42], CRISPR/Cas9 [28,30,38,43],
megaTAL nucleases [43] and engineered I-CreI homing endonucleases [29]. Although these techniques
do not edit 100% of cells, antibody coated magnetic bead depletion has been used to purify the end
product to >99% TCRαβ− cells, thus enabling their use in patients [36]. Pre-clinical work in murine
models suggests that gene editing techniques that knock out the TRAC loci, incorporating the CAR
construct into that site, may actually produce a more functional CAR-T cell product than current
methods used to generate PD CAR-T cells.
Rejection of CAR-T cells can occur in the PD CAR-T cell setting and is likely to be a greater
challenge with HD CAR-T cells. Murine derived elements of the CAR construct can be particularly
immunogenic. Lymphodepleting chemotherapy is required for successful expansion of infused cells
even when they are autologous. This is thought to be required to reduce the immunosuppressive host
cells such as regulatory T cells (Tregs). Intensification of lymphodepletion may allow non-HLA
matched cells to be given. In this context, proof of principle has been shown with the use of
Alemtuzumab which allows expansion of UCART19 (which has CD52 KO) [36]. When the host
immune system recovers, it would be expected to reject HLA mismatched cells. It is not yet clear
how long CAR-T cells need to persist to ensure a deep remission is achieved and this is likely to vary
between the different types of malignancy treated. Knocking out B2M, which is required for HLA class
I expression, may allow CAR-T cells to ‘hide’ from the host TCRαβ cells. This may be hampered by
activated T cells expressing HLA class II and NK cells targeting cells with reduced HLA expression.
Therefore, at present it seems unlikely that intensification of pre-conditioning chemotherapy can be
avoided. Whether the expected increased risk of infection for patients is manageable needs to be
carefully assessed in clinical trials. Certainly, there is optimism that gene editing can provide quick
access to CAR-T cell therapy at reduced cost, for a much wider group of patients who have the most
aggressive and resistant disease. It may also provide a more functional, potent, anti-cancer therapy.
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